Source - LSE Regulatory
RNS Number : 3331L
Tissue Regenix Group PLC
05 September 2023

Tissue Regenix Group plc

('Tissue Regenix', the 'Group' or the 'Company')


New sports medicine product launch


Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces the launch of its new BioRinse® product line for all sports medicine allografts that Tissue Regenix distributes in the US and internationally.


The Company's BioRinse sterilisation technology platform uses proprietary processes to produce sterile bone and soft tissue products. The new process for sports medicine allografts causes less damage to the tissue in order to produce an enhanced sterile soft tissue product. The primary market for these grafts is sports medicine, mainly consisting of tendon and ligament reconstruction procedures in the knee, ankle, elbow, and other joints.


The Company has previously discussed plans to innovate the processing protocols for its soft tissue products in order to enhance performance, efficiency, and safety in the products that Tissue Regenix already produces for the sports medicine market. These changes will allow Tissue Regenix to capture a larger segment of the estimated USD300 million market for allograft soft tissue tendons for ligament reconstruction procedures of the knee.


Daniel Lee, Chief Executive Officer of Tissue Regenix, commented: "As part of our ongoing initiatives to provide high-quality products to our customers, we continually monitor market dynamics and customer needs. With the launch of our new product, we are offering an enhanced tissue allograft option. The initial reaction of our commercial partners has been positive and will aid our commercial efforts in both the domestic and rest of the world markets."


For more information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

via Walbrook PR

finnCap Ltd (Nominated Adviser and Broker)

Emily Watts/Geoff Nash/George Dollemore - Corporate Finance

Nigel Birks/Harriet Ward - ECM


Walbrook PR (Financial PR and IR)

Tel: +44 (0)20 7933 8780

Alice Woodings/Lianne Applegarth


About Tissue Regenix (

Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.


In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Tissue Regenix Group PLC (TRX)

+0.50p (+0.81%)
delayed 15:57PM